血管造影后碳酸氢钠与乙酰半胱氨酸的结局
PRESERVE试验采用2×2析因设计,将5177例拟行血管造影的高危肾并发症患者随机分配至静脉1.26%碳酸氢钠或0.9%氯化钠,以及口服乙酰半胱氨酸5天或口服安慰剂,改良意向性分析纳入4993例。主要终点为90天死亡、需透析或血清肌酐较基线持续升高至少50%的复合终点。碳酸氢钠组主要终点发生率4.4%(110/2511) vs 氯化钠组4.7%(116/2482),OR 0.93(95%CI 0.72-1.22;P=0.62);乙酰半胱氨酸组4.6%(114/2495) vs 安慰剂组4.5%(112/2498),OR 1.02(95%CI 0.78-1.33;P=0.88)。造影剂相关急性肾损伤发生率组间无显著差异。
要点
- 高危肾并发症患者血管造影后,静脉碳酸氢钠组90天主要终点4.4%(110/2511) vs 氯化钠组4.7%(116/2482),OR 0.93(95%CI 0.72-1.22;P=0.62),无显著差异。
- 口服乙酰半胱氨酸组90天主要终点4.6%(114/2495) vs 安慰剂组4.5%(112/2498),OR 1.02(95%CI 0.78-1.33;P=0.88),无显著差异。
- 碳酸氢钠与乙酰半胱氨酸对主要终点无交互作用(P=0.33)。
- 造影剂相关急性肾损伤(次要终点)发生率组间无显著差异。
- 申办方在预设中期分析后终止了试验。
适用人群与场景
- 拟行血管造影的高危肾并发症患者。
处置流程与药物剂量
- 静脉1.26%碳酸氢钠或静脉0.9%氯化钠。
- 口服乙酰半胱氨酸或口服安慰剂,疗程5天。
研究设计与关键结果
- 研究类型:2×2析因设计随机对照试验;样本量:随机分配5177例,改良意向性分析纳入4993例;人群:拟行血管造影的高危肾并发症患者;干预与对照:静脉1.26%碳酸氢钠 vs 静脉0.9%氯化钠,口服乙酰半胱氨酸5天 vs 口服安慰剂;主要终点:90天死亡、需透析或血清肌酐较基线持续升高至少50%的复合终点;碳酸氢钠组110/2511(4.4%) vs 氯化钠组116/2482(4.7%),OR 0.93(95%CI 0.72-1.22;P=0.62);乙酰半胱氨酸组114/2495(4.6%) vs 安慰剂组112/2498(4.5%),OR 1.02(95%CI 0.78-1.33;P=0.88);碳酸氢钠与乙酰半胱氨酸对主要终点无交互作用(P=0.33);关键次要终点:造影剂相关急性肾损伤发生率组间无显著差异;申办方在预设中期分析后终止了试验。
证据类型、等级与局限
- 证据类型:随机对照试验;局限:申办方在预设中期分析后终止了试验。
对床旁实践的改变
- 在高危肾并发症患者中,静脉碳酸氢钠相比静脉氯化钠、口服乙酰半胱氨酸相比安慰剂,对预防90天死亡、需透析或肾功能持续下降以及造影剂相关急性肾损伤均无获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Intravenous sodium bicarbonate and oral acetylcysteine are widely used to prevent acute kidney injury and associated adverse outcomes after angiography without definitive evidence of their efficacy.
METHODS: Using a 2-by-2 factorial design, we randomly assigned 5177 patients at high risk for renal complications who were scheduled for angiography to receive intravenous 1.26% sodium bicarbonate or intravenous 0.9% sodium chloride and 5 days of oral acetylcysteine or oral placebo; of these patients, 4993 were included in the modified intention-to-treat analysis. The primary end point was a composite of death, the need for dialysis, or a persistent increase of at least 50% from baseline in the serum creatinine level at 90 days. Contrast-associated acute kidney injury was a secondary end point.
RESULTS: The sponsor stopped the trial after a prespecified interim analysis. There was no interaction between sodium bicarbonate and acetylcysteine with respect to the primary end point (P=0.33). The primary end point occurred in 110 of 2511 patients (4.4%) in the sodium bicarbonate group as compared with 116 of 2482 (4.7%) in the sodium chloride group (odds ratio, 0.93; 95% confidence interval [CI], 0.72 to 1.22; P=0.62) and in 114 of 2495 patients (4.6%) in the acetylcysteine group as compared with 112 of 2498 (4.5%) in the placebo group (odds ratio, 1.02; 95% CI, 0.78 to 1.33; P=0.88). There were no significant between-group differences in the rates of contrast-associated acute kidney injury.
CONCLUSIONS: Among patients at high risk for renal complications who were undergoing angiography, there was no benefit of intravenous sodium bicarbonate over intravenous sodium chloride or of oral acetylcysteine over placebo for the prevention of death, need for dialysis, or persistent decline in kidney function at 90 days or for the prevention of contrast-associated acute kidney injury. (Funded by the U.S. Department of Veterans Affairs Office of Research and Development and the National Health and Medical Research Council of Australia; PRESERVE ClinicalTrials.gov number, NCT01467466 .).
参考来源
- Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2017. PMID: 29130810. doi:10.1056/NEJMoa1710933
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。